Advertisement

Topics

Vicente Torres, M.D., Ph.D., discusses new findings on tolvaptan as autosomal dominant polycystic kidney disease treatment

20:00 EDT 3 Nov 2017 | Mayo Clinic

ROCHESTER, Minn. ? A phase 3 trial studying the effects of tolvaptan has found that the drug slowed the rate of decline in kidney function in patients with the most common form of polycystic kidney disease, a condition with no cure. The results are published today in the New England Journal of Medicine. Autosomal dominant [...]

Original Article: Vicente Torres, M.D., Ph.D., discusses new findings on tolvaptan as autosomal dominant polycystic kidney disease treatment

NEXT ARTICLE

More From BioPortfolio on "Vicente Torres, M.D., Ph.D., discusses new findings on tolvaptan as autosomal dominant polycystic kidney disease treatment"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Renal disease
Chronic kidney disease (CKD), also known as chronic renal disease, is a progressive loss in renal function over a period of months or years. The symptoms of worsening kidney function are non-specific, and might include feeling generally unwell and experi...

Nephrology - kidney function
Nephrology is a specialty of medicine and pediatrics that concerns itself with the study of normal kidney function, kidney problems, the treatment of kidney problems and renal replacement therapy (dialysis and kidney transplantation). Systemic conditions...